Document is current
Any future updates will be listed below
-
Authors
Hoshino, Shota
Takeuchi, Masashi
Kawakubo, Hirofumi
Matsuda, Satoru
Mayanagi, Shuhei
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Wada, Norihito
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 16 September 2020
Accepted: 11 December 2020
First Online: 10 March 2021
Disclosure
: Dr. Kitagawa reports grants from TAIHO PHARMACEUTICAL CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., Yakult Honsha Co. Ltd, DAIICHI SANKYO COMPANY, Merck Serono Co., Ltd, AsahiKASEI Co., Ltd, EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., SHIONOGI & CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc, MEDICON INC., DAINIPPON SUMITOMO PHARMA Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Pfizer Japan Inc., ONO PHARMACEUTICAL CO., LTD., NIHON PHARMACEUTICAL CO., LTD., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Sanofi K.K., Eisai Co., Ltd, TSUMURA & CO., KCI Licensing, Inc., ABBOTT JAPAN CO., LTD, and FUJIFILM Toyama Chemical Co., Ltd. outside the submitted work. Dr. Fukuda belongs to the Keio University School of Medicine Endowed Chair in Cancer Research (funded by CHUGAI PHARMACEUTICAL CO., LTD and TAIHO PHARMACEUTICAL CO., LTD).
